Puretech Health Share Discussion Threads

[volvo] 10/11/2021 07:25

Yes edward, that would be why they have just sold another $100m worth.

The gravy train keeps chugging on.

The markets don't seem like our cash position of nearly $500m....but how much is being splashed on mega expenses and wages and how much of valuable drug research?

[edwardt] 04/11/2021 09:07

Karuna going well...

[volvo] 22/10/2021 10:01

zipstuck exactly, market doesn't get it and is not happy with these partial investments.

It seems its up to PRTC to get their own pipeline up and running with LYT100 before the markets will start to give anything.

Year end now for Long Covid phase 2, which should read ok but not ground breaking

[zipstuck] 22/10/2021 09:23

Karuna at 129

[volvo] 22/10/2021 08:08

ed still knocking around.

Was very disappointed with the muted response re Vedanta results and the move to phase 3, and the general market apathy towards PTRC.

Making money else where, still holding a few at 340p

[lendmeafiver] 20/10/2021 22:30

Ha ha, he has moved on I think.

[edwardt] 20/10/2021 21:04

Volvo - given up? Normally revs his engine a bit more before moving on..

[salonie] 18/10/2021 18:40

ADVFN charts appear to be playing up, as this changed on the 1st attempt.

Anyway looks like there is a 50/200d ema possible golden cross on the chart coming or perhaps has already occurred, depending on what chart ADVFN decides to present!



free stock charts from uk.advfn.com

[rambutan2] 14/10/2021 15:24

Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary

Extensive legal experience with private and public biotech companies, including Biogen, IVAX Corporation and Cell Signaling Technology

CAMBRIDGE, MA, October 14, 2021 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced the appointment of Simona Levi, Ph.D., J.D., as Chief Legal Officer and Corporate Secretary. Dr. Levi brings over 25 years of United States and international legal experience with private and public companies across the life sciences industry focusing on complex transactions, intellectual property law and litigation, and corporate governance.

“Simona’s deep legal experience and proven track record in the life sciences industry will be critical as we execute on our vision to enable a new class of drugs in the microbiome field,” said Bernat Olle, Ph.D., Co-Founder and Chief Executive Officer of Vedanta Biosciences. “We are excited to welcome Simona to the Vedanta team and look forward to her contributions.”;

Dr. Levi joins Vedanta from Cell Signaling Technology (CST), Inc., where she served as the general counsel and corporate secretary managing all legal matters including assisting with the formation of the company’s global subsidiaries and structuring all financial transactions. Dr. Levi spent more than 25 years working as legal counsel for corporate and intellectual property matters in the life sciences industry. Most notably, she was a partner at the law firm McDermott Will & Emery, served as director of neurology for Biogen, and was a senior IP counsel for IVAX Corporation.

Dr. Levi has a B.A. in biochemistry and economics, a Ph.D. in biochemistry from Rutgers University and a J.D. from the University of Pennsylvania Law School. Dr. Levi has been a member of the Massachusetts Bar Association since 1995.

“With the recent activity and interest in the microbiome field, it has become clear that Vedanta has shown great promise in pioneering defined bacterial consortia as a new class of therapeutics,” said Dr. Levi. “Vedanta has assembled a talented and dedicated team and I am thrilled to be joining such a dynamic company at this pivotal stage of its growth.”

[edwardt] 11/10/2021 14:44

whne does the spac list for gelesis - i see they have 44k users now. not bad.

[volvo] 08/10/2021 18:49

Yes Puretech have been banging the drum....hence the new presentation, which is kind of compelling.

Dirt cheap, add in the royalties via Gelesis and Karuna....all makes Puretech a buy out candidate.

Might never happen.....but who knows, LYT100 looks a shoe atm, probably worth our market cap on its own, forget the $400m cash or the founded entities, Karuna , Vedanta, Gelesis, Akili, Sonde, Vor, Folica, Entregra.

[lendmeafiver] 08/10/2021 18:16

I don’t think it needs to be a complete miracle cure to be a valuable treatment with a good business model.

[rambutan2] 08/10/2021 17:27

I can guarantee that if it works, out of all of PRTC's portfolio treatments it will be the one which hits the real world headlines!

[lendmeafiver] 08/10/2021 17:12

You cynic Ed! a 44% increase in visible hair after 3 months is better than anything else available to the market, must be worth something, plus maybe multi treatments are possible.

[edwardt] 08/10/2021 15:56

thanks for that . the hair growth business still feels suspect to me, the picture in the slide deck looks like a classic comb over to me!

[volvo] 07/10/2021 19:56

.....now 316k, probably nothing, but who knows.

[lendmeafiver] 07/10/2021 19:06

That’s a huge rise in volume, encouraging.

[volvo] 07/10/2021 18:26

Hello....Nasdaq up 7pc 376p on massive vol 286k which is 8 times higher than normal, sumatts up

[volvo] 07/10/2021 09:14

lmaf, having waited for the Vedanta results for the phase2 VE303, it is disappointing to see the share price under pressure, it should indeed be pushing 400p plus.

The results were good enough for BARDA to finance phase3 in 2022, it has financed VE303 to the tune of $70m so far. Nothing to PRTC even though it owns 41pc of Vedanta.

As you say, positive LYT100 results in phase 2 for Long Covid, might liven the market up.

[lendmeafiver] 06/10/2021 17:24

Agree, I think the deupirfenidone results that must be due imminently, will catch the attention of the market.

[edwardt] 06/10/2021 10:02

vedanta - i guess the probability of success must have gone up to over 50%. if it is best in class product for c-dif which i have no reason to believe it couldn't be from the evidence - we may have a circa £1.5bn sales product on our hands. nice.

[volvo] 05/10/2021 14:27

Vedanta VE303 news is out and its positive....markets in the LSE haven't got a clue....we own 41pc of Vedanta, going for phase 3 trial next year, and will launch on Nasdaq shortly....all EXCELLENT news for
Puretech....BARDA exercises $23.8 million option to support Phase 3 clinical trial of VE303, to initiate in 2022....they fancy it as well.

Other news from Sonde too, all positive.

Hopefully the Nasdaq can lead the way

[volvo] 04/10/2021 15:54

Just come to see this at 338p to buy, thanks very much another 3k to the porfolio

[lendmeafiver] 03/10/2021 22:19

Interesting, thanks.